Ilyang Pharmaceutical’s Parkinson’s disease drug candidate ‘Supect’ stated in international SCI journal
Ilyang Pharmaceutical(CEO Dong-Yeon Kim) announced ‘Supect(generic name: radotinib),’ the 18th Korean new drug candidate for the treatment of Parkinson’s disease, was approved to be published in ‘Human Molecular Genetics,’ an international SCI journal.
With the impact factor of 5.34, ‘Human Mole...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
